PU535 Unit 8 Global Burden Review Example

The Same Sore Throat, a Hundredfold Difference in Heart Disease: A Unit 8 Global Burden Review Comparing Rheumatic Heart Disease in a Composite High-Income and Low-Income Country and Ranking Four Explanations for the Gap

[Student Name]

Purdue University Global

PU535: Public Health Biology - A Global Perspective

Unit 8 Global Burden Review

[Instructor Name]

[Date]

The two countries are composite and their figures are drawn from published regional ranges; the mechanism, the prevention evidence and the research cited are real.

The Puzzle in Two Measurements

Streptococcal pharyngitis is a common childhood infection in both of the composite countries in this review. Country A is high income, with 1.2 cases of rheumatic heart disease per 100,000 school-aged children. Country B is low income, where echocardiographic screening of schoolchildren finds 30 or more cases per 1,000. The infection rate differs little; the heart disease rate differs by nearly two orders of magnitude. Since the organism is the same, the difference must lie in what happens between the throat and the valve.

The Burden Figures and Where They Come From

1. Global prevalence of rheumatic heart disease: more than 30 million people, with the great majority in low and middle income countries, and an estimated 300,000 deaths a year (Watkins et al., 2017).

2. Country A, high income: rheumatic fever now a reportable rarity, concentrated in a few indigenous and low-income communities.

3. Country B, low income: prevalence of 30 per 1,000 schoolchildren when echocardiography is used, against roughly 2 per 1,000 when only a stethoscope is used.

The second contrast inside Country B is itself a finding. Screening by echocardiography in school populations detects many times more disease than clinical examination, because most affected valves are not yet audible to a listener (Marijon et al., 2007). Any comparison of burden between countries therefore has to say which instrument produced each number, and this review uses echocardiographic prevalence for both.

The Mechanism That Links Throat to Valve

The damage is not done by the organism reaching the heart. After a streptococcal throat infection, the immune response in a susceptible person can cross-react with heart tissue, because some bacterial surface proteins resemble proteins in the heart valve. The resulting inflammation is acute rheumatic fever, which affects joints, heart, skin and nervous system; the joints recover and the valves do not. What makes the disease chronic is repetition, since each further episode adds scarring to a valve already damaged, until the valve leaks or narrows enough to cause heart failure. This explains the single most important fact about prevention: the target is not one infection but the series. Country B's children do not have a different disease. They have the same first episode and then the second, third and fourth that Country A's children never get.

Four Explanations, Ranked

1. Repeated exposure in crowded housing. This ranks first. Household crowding raises the number of streptococcal infections a child has before adolescence, and the risk of chronic valve disease rises with the number of episodes. Country A's decline began well before any specific treatment program and tracked housing, household size and general living conditions rather than medical care, which is the central lesson of the historical analysis of its disappearance in the United States (Gordis, 1985).

2. Untreated and unrecognized sore throat. This ranks second. Treating streptococcal pharyngitis with penicillin reduces the chance that an episode is followed by rheumatic fever, with pooled trial evidence showing a substantial reduction, though the trials were conducted in military populations and their numbers do not transfer directly to village clinics (Robertson et al., 2005). In Country B, most sore throats never reach a clinician who could test or treat them.

3. Failure of secondary prophylaxis. This ranks third, and it is where the clearest avoidable harm sits. A person who has had rheumatic fever needs an injection of long-acting penicillin every 21 to 28 days for years to prevent the next episode. Country A's few patients receive it through registers that track them. Country B has no register, supply is intermittent, and a child who misses three months loses the protection entirely.

4. Differences in the organism or in genetic susceptibility. This ranks last. Strain differences and inherited susceptibility are real and account for why only a minority of infected children develop rheumatic fever anywhere, but they cannot explain a hundredfold gap between populations in which the infection is equally common, and they change nothing a program can act on.

A Gap Inside Wealthy Countries Too

Country A's national rate hides its own inequality. Rheumatic fever persists in its crowded, low-income and indigenous communities at rates closer to Country B's than to its own average, which is the strongest available test of the ranking above. The organism and the health system are national; the housing is not, and the disease follows the housing. The global burden estimates make the same point at scale, finding that the countries carrying the heaviest burden are those where crowding and limited access to primary care coincide (Carapetis et al., 2005).

What the Injection Schedule Demands of a Program

The interval between injections is worth one paragraph of its own, because it decides what kind of program can deliver prevention at all. Long-acting penicillin given every 21 to 28 days keeps a concentration in the blood high enough to prevent a new streptococcal infection from taking hold; by week five the protection is gone. A child who had rheumatic fever at eight needs that injection on schedule into early adulthood, which is well over a hundred visits. No campaign, no awareness week and no single clinic encounter can produce that. It requires a named list of patients, a clinic that knows when each is due, a worker who follows up the ones who do not come, and a supply that does not run out in the dry season. Country A's rarity is maintained by exactly such lists, and Country B's burden persists partly because the lists do not exist.

What the Comparison Recommends

For Country B, the review recommends a patient register and a reliable supply of long-acting penicillin first, because secondary prophylaxis is the measure with the best evidence per dollar and the people who need it are already identified by their first episode. It recommends school-based echocardiographic screening second, and only where a register exists to receive the cases found, since screening that finds valve disease and offers nothing is not a program. It does not recommend mass treatment of sore throats, since the number needing treatment to prevent one case is large and the clinical capacity does not exist. For Country A, it recommends that national figures be reported by community, because an average that conceals a twenty-fold internal difference will keep the problem invisible.

What the Review Cannot Settle

The two countries are composite, and real comparisons are harder because surveillance differs: Country A counts notified rheumatic fever and Country B's prevalence comes from research screening, so part of any measured gap is measurement. Nor can a review of this kind separate crowding from the other things that travel with it, including nutrition, co-infection and distance from care. What it can establish is the ordering, because the historical decline in high-income countries preceded the interventions that are often credited with it, and that sequence constrains any explanation.

References

Carapetis, J. R., Steer, A. C., Mulholland, E. K., & Weber, M. (2005). The global burden of group A streptococcal diseases. The Lancet Infectious Diseases, 5(11), 685-694. https://doi.org/10.1016/S1473-3099(05)70267-X

Gordis, L. (1985). The virtual disappearance of rheumatic fever in the United States: Lessons in the rise and fall of disease. Circulation, 72(6), 1155-1162. https://doi.org/10.1161/01.CIR.72.6.1155

Marijon, E., Ou, P., Celermajer, D. S., Ferreira, B., Mocumbi, A. O., Jani, D., Paquet, C., Jacob, S., Sidi, D., & Jouven, X. (2007). Prevalence of rheumatic heart disease detected by echocardiographic screening. The New England Journal of Medicine, 357(5), 470-476. https://doi.org/10.1056/NEJMoa065085

Robertson, K. A., Volmink, J. A., & Mayosi, B. M. (2005). Antibiotics for the primary prevention of acute rheumatic fever: A meta-analysis. BMC Cardiovascular Disorders, 5, 11. https://doi.org/10.1186/1471-2261-5-11

Watkins, D. A., Johnson, C. O., Colquhoun, S. M., Karthikeyan, G., Beaton, A., Bukhman, G., Forouzanfar, M. H., Longenecker, C. T., Mayosi, B. M., Nascimento, B. R., Ribeiro, A. L. P., Sable, C. A., Steer, A. C., Naghavi, M., Mokdad, A. H., Murray, C. J. L., Vos, T., Carapetis, J. R., & Roth, G. A. (2017). Global, regional, and national burden of rheumatic heart disease, 1990-2015. The New England Journal of Medicine, 377(8), 713-722. https://doi.org/10.1056/NEJMoa1603693